Guardant Health soars on strong Q2 results, raises 2025 outlook

Published 30/07/2025, 21:56
Guardant Health soars on strong Q2 results, raises 2025 outlook

Investing.com -- Guardant Health Inc (NASDAQ:GH) shares surged 5.7% after the cancer testing company reported better-than-expected second quarter results and raised its full-year guidance, driven by strong performance across all business segments.

The precision oncology company posted a second quarter adjusted loss of -$0.44 per share, significantly better than analysts’ expectations of -$0.72 per share. Revenue jumped 31% YoY to $232.1 million, comfortably exceeding the consensus estimate of $211.27 million.

Oncology revenue, which accounts for the largest portion of Guardant’s business, increased 22% to $158.7 million, with test volume growing 30% compared to the same period last year. The company’s screening segment generated $14.8 million from approximately 16,000 Shield tests, while biopharma and data revenue rose 28% to $56 million.

"Q2 was another exceptional quarter for Guardant and we were able to increase our 2025 revenue guidance yet again. We saw especially strong performance from Guardant360 Liquid, where year-over-year growth accelerated for the fourth consecutive quarter," said Helmy Eltoukhy, co-founder and co-CEO.

Guardant Health raised its full-year 2025 revenue guidance to between $915 million and $925 million, representing growth of 24-25% compared to 2024. This outlook significantly exceeds the analyst consensus of $885.1 million. The company also improved its non-GAAP gross margin forecast to 63-64%, up from previous expectations of 62-63%.

The improved outlook reflects stronger growth across all segments. Oncology revenue is now expected to grow approximately 20% YoY, up from prior guidance of 18%. Screening revenue forecasts were substantially increased to $55-60 million, compared to the previous range of $40-45 million, driven by higher Shield test volumes.

Guardant Health maintained its expectation to reach free cash flow breakeven in its core business, excluding screening, by the fourth quarter of 2025.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.